Lane Clark & Peacock LLP

ID 135-5

The results of this study’ll allow us to identify patient groups who will benefit the most clinically, so that targeting treatment to these groups result in the largest reduction in healthcare burden and more equitable health outcomes for the population.

The number of patients living with chronic diseases such as cardiovascular disease (CVD) has increased substantially in recent years. The health impacts, both CVD-specific and broader health impacts, are likely to vary substantially across the large CVD population according to a range of factors including risk factors (demographic, physiological and behavioural) and comorbidities. The health trajectories, hence potential impacts, of therapeutics vary within populations more than ever, and cannot be comprehensively captured through trials. Health systems generally do not account for these big variations in unmet health need. In order for CVD treatments to be targeted to patients with the greatest unmet need, health systems need to understand the patterns of health risks and treatment impacts within their patient population, to understand which patients will benefit the most from these treatments. To this end, we will evaluate the variation in unmet need in patients with CVD, estimate the potential benefits of CVD therapeutic interventions on health trajectories and assess the reduction in healthcare burdens across CVD subgroups. The primary aim of this research is to use the large-scale, linked Discover-NOW resource to identify characteristics of subgroups of patients with cardiovascular disease (CVD) who have the highest unmet clinical need (CVD events), hence are likely to experience the greatest clinical benefit from specific CVD therapeutics. Additionally, we aim to estimate HCRU and costs as a proxy for total health need in the CVD population and map how this varies across subgroups of the population. We aim to develop projections for each sub-group to estimate future healthcare need. Lastly, we aim to develop a visualisation platform to clearly communicate findings with regards to CVD and total health need across the CVD population and risk stratify sub-groups according to health need and potential impact of interventions. This would enable healthcare providers to more proportionately target patients with the highest unmet need today and in the future, in order to reduce inequalities in CVD burden, poor health outcomes and healthcare costs to the healthcare provider.

21/09/2023

TRE